Emerald Advisers Inc. PA lowered its position in shares of Acadia Healthcare Co. (NASDAQ:ACHC) by 11.5% during the second quarter, Holdings Channel reports. The institutional investor owned 338,002 shares of the company’s stock after selling 43,896 shares during the period. Emerald Advisers Inc. PA’s holdings in Acadia Healthcare were worth $18,725,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Rice Hall James & Associates LLC boosted its stake in Acadia Healthcare by 19.4% in the second quarter. Rice Hall James & Associates LLC now owns 38,403 shares of the company’s stock worth $2,128,000 after buying an additional 6,241 shares in the last quarter. GW&K Investment Management LLC boosted its stake in Acadia Healthcare by 36.3% in the second quarter. GW&K Investment Management LLC now owns 280,826 shares of the company’s stock worth $15,558,000 after buying an additional 74,842 shares in the last quarter. American Century Companies Inc. acquired a new stake in Acadia Healthcare during the second quarter worth $56,657,000. RS Investment Management Co. LLC boosted its stake in Acadia Healthcare by 2.6% in the second quarter. RS Investment Management Co. LLC now owns 644,586 shares of the company’s stock worth $35,710,000 after buying an additional 16,497 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in Acadia Healthcare during the second quarter worth $14,020,000.
Acadia Healthcare Co. (NASDAQ:ACHC) traded up 1.06% on Tuesday, reaching $49.41. The company’s stock had a trading volume of 533,018 shares. The stock’s 50 day moving average price is $50.84 and its 200 day moving average price is $55.15. Acadia Healthcare Co. has a 12 month low of $46.99 and a 12 month high of $74.77. The company has a market cap of $4.32 billion, a P/E ratio of 26.39 and a beta of 0.86.
Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Friday, July 29th. The company reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Acadia Healthcare had a return on equity of 9.35% and a net margin of 6.44%. The firm earned $756.50 million during the quarter, compared to analysts’ expectations of $752.57 million. During the same period in the prior year, the company earned $0.57 earnings per share. The company’s quarterly revenue was up 66.8% on a year-over-year basis. Equities research analysts forecast that Acadia Healthcare Co. will post $2.63 earnings per share for the current year.
A number of research firms recently weighed in on ACHC. Zacks Investment Research raised Acadia Healthcare from a “sell” rating to a “hold” rating in a report on Monday. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $61.00 price target on shares of Acadia Healthcare in a report on Tuesday, September 27th. Leerink Swann reaffirmed an “outperform” rating and set a $80.00 price target on shares of Acadia Healthcare in a report on Monday, September 26th. Robert W. Baird lowered their target price on Acadia Healthcare from $67.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, September 15th. Finally, RBC Capital Markets reissued an “outperform” rating and issued a $78.00 target price (down from $86.00) on shares of Acadia Healthcare in a research note on Monday, August 1st. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $77.21.
In other Acadia Healthcare news, Director Reeve B. Waud sold 1,360,977 shares of the company’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $48.52, for a total transaction of $66,034,604.04. Following the completion of the sale, the director now directly owns 55,673 shares in the company, valued at $2,701,253.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO David M. Duckworth sold 16,670 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $54.33, for a total value of $905,681.10. Following the sale, the chief financial officer now owns 11,688 shares of the company’s stock, valued at $635,009.04. The disclosure for this sale can be found here. Company insiders own 17.20% of the company’s stock.
About Acadia Healthcare
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.
Want to see what other hedge funds are holding ACHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acadia Healthcare Co. (NASDAQ:ACHC).
Receive News & Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.